Faron Pharmaceuticals: Updated Clinical Data from BEXMAB Study - Redeye

Redeye provides a short update following Faron’s recent clinical data update from the phase I/II BEXMAB study with its lead candidate, bexmarilimab. Overall, we are encouraged by the candidate’s continued positive advancements and high response rate in relapsed/refractory AML and MDS.

Länk till analysen i sin helhet: https://www.redeye.se/research/946451/faron-pharmaceuticals-updated-clinical-data-from-bexmab-study?utm_source=finwire&utm_medium=RSS